

REMARKS

COMPLIANCE WITH 37 C.F.R. §§ 1.821 – 1.825

The Notice to Comply attached to the Office Action mailed February 26, 2007, has been received and reviewed. The Notice to Comply alleges that the Application fails to comply with the sequence listing rules under 37 C.F.R. §§ 1.821 – 1.825, because peptide sequences appearing in the originally-filed Specification were not identified by a sequence identifier in accordance with 37 C.F.R. § 1.821(d). The Notice to Comply further states: “Extensive amendments may necessitate submission of a substitute specification.”

In order to bring the Application in compliance with the sequence listing rules under 37 C.F.R. §§ 1.821 – 1.825, Applicants have reviewed the entire Specification and inserted sequence identifiers wherever a peptide sequence was presented. Due to the extensive nature of the amendments necessitated, Applicants submit herewith a Substitute Specification, in compliance with 37 C.F.R. § 1.121(b)(3). In the Substitute Specification submitted herewith, every sequence is now accompanied by a “SEQ ID NO:” designation in compliance with 37 C.F.R. §§ 1.821 – 1.825.

Applicants note that each of the sequences appearing in the Specification – including those for which sequence identifiers have been added in the Substitute Specification – was listed in the Replacement Sequence Listing, which was filed on Compact Disk, on November 17, 2006. Consequently, since no new sequence identifiers were needed, there is no need to file a Substitute Sequence Listing with this Response.

Applicants believe that upon entry of the Substitute Specification provided herewith, the Application will be in full compliance with the requirements of 37 C.F.R. § 1.821 through 1.825.

Appl. No. 10/663,407

Response dated May 21, 2007

Reply to Notice to Comply of February 26, 2007

It is also believed that no extension of time or additional fee is due with this response. If this is incorrect, an extension of time as deemed necessary is hereby requested, and the Commissioner is hereby authorized to charge any appropriate fees or deficiency, or credit any over payment, to Deposit Account no. **50-1627**.

Respectfully submitted,

/Herbert L. Ley III/

Herbert L. Ley III, Ph.D.
Registration No. 53,215

Date: May 21, 2007

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871